
©Pharaoh Hound (WikiCommons 2.0)
A colony of dogs has been maintained at Queen’s since 1981 for use in hemophilia research (miniature schnauzers, spaniels and beagles). This ongoing research project is instructive for thinking about the ethics of using animals for biomedical research to benefit humans, and the need for genuine public oversight.
Hemophilia is a rare blood clotting disorder, affecting approximately 3000 Canadians. Current treatment, which is highly effective, is to replace the missing clotting factor either on an as-needs basis if a bleed occurs, or as part of ongoing prophylactic treatment (self-injection with the deficient clotting factor 3 times per week). The standard treatment has improved significantly in recent decades, and most people with hemophilia can now live a normal life span, with excellent quality of life, although a minority of patients develop inhibitors (a rejection response to clotting factor) making their treatment more complex.
The Queen’s colony includes dogs purpose-bred to have hemophilia, as well as non-diseased dogs to serve as research controls, or as blood donors for the hemophilia dogs who need regular transfusions. As noted in this article, these dogs are used for experiments over and over again, into old age. Dogs in other hemophilia research colonies, like University of North Carolina at Chapel Hill, at least have outdoor runs, and access to a one acre outdoor play area. Not so for the Queen’s dogs who spend their entire lives in the lab.
Originally the Queen’s dogs were used to refine the standard infusion treatments for humans with hemophilia, and to study the problem of inhibitors. More recently, however, the dogs have been used for to explore gene transfer techniques as a possible treatment for hemophilia A (the common form of the disease which accounts for approximately 80% of cases). Here is the pubmed link to a 2014 gene therapy study conducted at Queen’s.
Continue Reading